


Product Details

Catalog No.	ATAD00272
INN (International Nonproprietary Name)	Caplacizumab
Purity	>95%

SDS-PAGE image



Concentration	1.6 mg/ml
Formulation	20mM Citric acid,6.2% sucrose,0.01% Tween 80
Source	CHO cells
Endotoxin level	Please contact with the lab for this information.
Note	For research use only .

Bioactivity

Description	Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,6 and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.
Alternative names	ALX-0081,PMP12A2h1-linker AAA-PMP12A2h1,caplacizumab-yhdp
Specificity target name;species	VWF A1 domain[Homo sapiens]
Species	Humanized
Receptor identification	VH-VH

Chemistry

MV

30 kDa

CAS

915810-67-2

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

